IQE PLC
IQE develops and manufactures advanced semiconductor wafers used in wireless and photonics devices. Recent multi-year supply agreements with MACOM and Tower Semiconductor have driven an eightfold price rise in six months despite ongoing losses.
Why the signal matters
Tracked account flagged IQE as the sole European gainer amid volatility in other holdings.
The post highlights a concentrated winner in a basket of small-cap semis; the rapid move from the $12-13 entry aligns with the 2026 supply announcements.
The thesis, broken down and checked against the data:
Supply chain wins
June 2026 multi-year InP epiwafer deal with Tower and MACOM long-term agreements directly address revenue visibility in photonics and wireless. These contracts sit against 0.1% YoY revenue growth and could lift utilization.
Insider alignment
24.1% insider ownership plus documented 2023 CEO purchases show skin in the game; this stake size exceeds typical levels and reduces near-term dilution risk.
Valuation on growth
Forward P/E of 50.76 and P/S 7.37x price in recovery; current negative EBITDA of GBX -8.21M means any margin expansion from new volumes would expand earnings sharply.
High beta momentum
Beta 2.25 and 831.5% run from 4.965 low amplify both upside from deals and downside if orders slip; 52-week range shows prior 90% drawdowns.
The flagged move is real and tied to contracts, yet thin revenue and negative margins mean the thesis rests on execution that has not yet appeared in results.
What IQE actually does
IQE grows compound semiconductor layers on wafers sold to chip makers.
The company operates three segments—Wireless, Photonics, and CMOS++—producing epitaxial wafers for radio-frequency devices in 5G phones and infrastructure plus photonic components that emit or detect light for data centers and sensors. Revenue comes from long-term supply contracts priced per wafer; customers such as MACOM and Tower integrate the wafers into finished chips. Because IQE supplies the foundational material rather than finished devices, margins depend on utilization rates and mix of higher-value InP or GaAs wafers. New multi-year agreements can compound if they raise fab loading above breakeven, turning the current negative EBITDA into operating leverage.
No segment revenue split provided in source data.
Competitive landscape
IQE is a specialized epiwafer foundry rather than an equipment or device maker.
The market for compound semiconductor substrates and epiwafers is fragmented; a handful of specialists serve the same wireless and photonics customers while larger silicon players dominate CMOS. IQE holds a niche position as a pure-play European supplier with InP and GaAs capability, sitting between equipment vendors and integrated device makers. Its edge is process know-how and existing capacity rather than scale or vertical integration.
Who else plays in this theme:
Process recipes and customer qualifications in InP photonics that take years to replicate.
Price action and valuation context
Shares exploded from sub-5p to the mid-40s on 2026 contract news.
From the Dec 2025 low of 4.965 the stock rose 831.5% to 46.25 by mid-June 2026, far outpacing the broader market and turning a 4-month position into a multi-bagger for the flagged account.
The move coincided with the April MACOM supply-chain strengthening announcement and the June Tower InP epiwafer agreement, shifting the narrative from chronic losses to visible revenue recovery.
At 7.37x sales and 50.76x forward earnings the valuation already prices in margin normalization; any delay in contract ramp would compress multiples quickly given current negative margins.
Prior history shows repeated boom-bust cycles—shares traded above 70p then fell below 5p—consistent with the 2.25 beta and cyclical semiconductor demand.
Key metrics vs sector
Profitability remains deeply negative while forward multiples assume recovery.
| Metric | This stock | Sector | What it tells you |
|---|---|---|---|
| P/E | n/a | n/a for loss-makers | No current earnings |
| Forward P/E | 50.76 | rich vs peers | Assumes profit rebound |
| P/S | 7.37x | rich vs peers | Premium for growth story |
| P/B | 6.77x | rich vs peers | Above book despite losses |
| EV/EBITDA | 27.26x | rich vs peers | Ignores negative EBITDA |
| Profit margin | -37.7% | below average | Deeply unprofitable |
| Operating margin | -19.6% | below average | Operating losses |
| ROE | -32.8% | below average | Value destruction |
| Rev growth YoY | 0.1% | below average | Flat revenue |
| Dividend yield | n/a | n/a | No dividend |
Balance sheet and runway
Debt exceeds cash and equity; leverage is the central constraint.
Cash of GBX 15.65M against GBX 91.69M debt leaves net debt near GBX 76M, larger than the GBX 89.69M equity base. Total liabilities of GBX 123.64M exceed total assets of GBX 213.34M only modestly, yet the negative EBITDA of GBX -8.21M means interest coverage relies on new contract cash flows. Without fresh equity or rapid margin improvement the balance sheet limits flexibility for capacity expansion or downturns.
Concrete risks
Four specific flags stand out from the data.
Ownership structure
Insiders hold a large stake while institutions provide additional backing.
High insider ownership aligns management with shareholders; low short interest reduces squeeze risk but also limits immediate contrarian fuel.
Catalyst timeline
Next results and contract ramps are the key dates.
Investors will watch whether the new agreements appear in revenue by the next earnings print and whether margins begin to inflect from current negative levels.
How to buy
Trade on the London Stock Exchange under ticker IQE.
UK-listed; non-UK investors should check FX conversion and any local custody fees. Thin reported volume warrants small starter positions.